<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10027318</article-id><article-id pub-id-type="pmc">2362406</article-id><article-id pub-id-type="pii">6690076</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690076</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Frontini</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Comella</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barni</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Labianca</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Battelli</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Casaretti</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zonato</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pirovano</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Catalano</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cellerino</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Departments and Units of Medical Oncology, Ancona, Naples, Milan, Monza, Pesaro, Italy</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Sezione di Oncologia Sperimentale, Unit&#x000e0; Operativa di Oncologia Medica, Azienda Ospedaliera &#x02018;Ospedale S. Salvatore&#x02019; Pesaro, Via Lombroso 61100 Pesaro, Italy</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>1999</year></pub-date><volume>79</volume><issue>3-4</issue><fpage>491</fpage><lpage>494</lpage><history><date date-type="received"><day>17</day><month>12</month><year>1997</year></date><date date-type="rev-recd"><day>24</day><month>03</month><year>1998</year></date><date date-type="accepted"><day>15</day><month>06</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m<sup>&#x02212;2</sup>, 5-fluorouracil 500 mg m<sup>&#x02212;2</sup>, epidoxorubicin 35 mg m<sup>&#x02212;2</sup>, 6S stereoisomer of leucovorin 250 mg m<sup>&#x02212;2</sup> and glutathione 1.5 mg m<sup>&#x02212;2</sup>, supported by a daily administration of lenograstim at a dose of 5 &#x003bc;g kg<sup>&#x02212;1</sup>. Nineteen patients were men and three were women. Median age was 63 years (range 47&#x02013;70). At study entry, pain was present in 15 out of 22 patients (68&#x00025;) with a mean value of Scott&#x02013;Huskisson scale of 27.6 &#x000b1; 23.8, whereas a weight loss &#x0003e;10&#x00025; was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13&#x00025; (95&#x00025; CI 0&#x02013;26&#x00025;), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40&#x00025;) with a mean value of Scott&#x02013;Huskisson scale of 12.3 &#x000b1; 18.4. Eight patients (36&#x00025;) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7&#x00025;), of neutropenia in 9 out of 188 cycles (4.7&#x00025;) and of thrombocytopenia in 3 out of 188 cycles (1.5&#x00025;). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>pancreatic cancer</kwd><kwd>intensive chemotherapy</kwd><kwd>palliation</kwd></kwd-group></article-meta></front></article>
